| Sarah-anne Victoria Galloway, APRN | |
|
2800 10th Ave N, Billings, MT 59101-0703 | |
| (406) 657-4145 | |
| (406) 657-4137 |
| Full Name | Sarah-anne Victoria Galloway |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 2800 10th Ave N, Billings, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114462124 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 131634 (Montana) | Primary |
| 363LF0000X | Nurse Practitioner - Family | 29441.1590 (Wyoming) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Billings Clinic | Billings, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Clinic | 6002993516 | 659 |
News Archive
Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.
Professor Debbie Lawlor and colleagues used two approaches to test the 'developmental overnutrition' hypothesis which asserts that if a woman is overweight during pregnancy, high sugar and fat levels in her body might permanently affect her growing baby's appetite control and metabolism, thus increasing the child's risk of becoming obese in later life.
A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.
› Verified 5 days ago
| Entity Name | Big Horn Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891713533 PECOS PAC ID: 5092612796 Enrollment ID: O20031218000807 |
News Archive
Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.
Professor Debbie Lawlor and colleagues used two approaches to test the 'developmental overnutrition' hypothesis which asserts that if a woman is overweight during pregnancy, high sugar and fat levels in her body might permanently affect her growing baby's appetite control and metabolism, thus increasing the child's risk of becoming obese in later life.
A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.
› Verified 5 days ago
| Entity Name | Stillwater Hospital Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053488387 PECOS PAC ID: 6406889815 Enrollment ID: O20050915001057 |
News Archive
Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.
Professor Debbie Lawlor and colleagues used two approaches to test the 'developmental overnutrition' hypothesis which asserts that if a woman is overweight during pregnancy, high sugar and fat levels in her body might permanently affect her growing baby's appetite control and metabolism, thus increasing the child's risk of becoming obese in later life.
A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.
› Verified 5 days ago
| Entity Name | Billings Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326104845 PECOS PAC ID: 6002993516 Enrollment ID: O20080430000212 |
News Archive
Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.
Professor Debbie Lawlor and colleagues used two approaches to test the 'developmental overnutrition' hypothesis which asserts that if a woman is overweight during pregnancy, high sugar and fat levels in her body might permanently affect her growing baby's appetite control and metabolism, thus increasing the child's risk of becoming obese in later life.
A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah-anne Victoria Galloway, APRN Po Box 37000, Billings, MT 59107-7000 Ph: (406) 657-4145 | Sarah-anne Victoria Galloway, APRN 2800 10th Ave N, Billings, MT 59101-0703 Ph: (406) 657-4145 |
News Archive
Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.
Professor Debbie Lawlor and colleagues used two approaches to test the 'developmental overnutrition' hypothesis which asserts that if a woman is overweight during pregnancy, high sugar and fat levels in her body might permanently affect her growing baby's appetite control and metabolism, thus increasing the child's risk of becoming obese in later life.
A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.
› Verified 5 days ago
Anna Victoria Nesovic, DNP, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave N, Billings, MT 59101 Phone: 406-672-0927 | |
Rebekah Lee Brady, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 435-851-9636 | |
Jeanne Randale Conner, MN, APRN, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3318 3rd Ave N, Billings, MT 59101 Phone: 406-248-3149 Fax: 406-245-6636 | |
Theresa Marie Shelton, NNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 7417 Monad Rd, Billings, MT 59106 Phone: 406-861-0783 | |
Tish Ann Marie Parker, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 602 Henry Chapple St, Billings, MT 59106 Phone: 406-901-2300 | |
Melinda M Truesdell, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
Anne Evelyn Mcrae, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1020 N 27th St, 410, Billings, MT 59102 Phone: 406-255-8550 |